Mis­lead­ing ex­hib­it booth pan­el lands NJ drug­mak­er an un­ti­tled let­ter from FDA

Eden­bridge Phar­ma­ceu­ti­cals re­ceived this year’s first un­ti­tled let­ter from the FDA’s drug pro­mo­tion of­fice over mis­lead­ing claims in an ad­ver­tise­ment for the com­pa­ny’s mul­ti­ple myelo­ma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER